Sol-Gel Technologies

About Sol-Gel Technologies

Sol-Gel Technologies (Nasdaq: SLGL) is a dermatology-focused biopharma company. In 2026, the company is preparing for Q4 top-line results from its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, while its FDA-approved products TWYNEO and EPSOLAY are launching in international territories.